Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (9)
  • Open Access

    ARTICLE

    Identifying and validating MMP family members (MMP2, MMP9, MMP12, and MMP16) as therapeutic targets and biomarkers in kidney renal clear cell carcinoma (KIRC)

    KUNLUN LI1, DANDAN LI2, BARBOD HAFEZ3,*, MOUNIR M. SALEM BEKHIT4, YOUSEF A. BIN JARDAN4, FARS KAED ALANAZI4, EHAB I. TAHA4, SAYED H. AUDA4, FAIQAH RAMZAN5,*, MUHAMMAD JAMIL6

    Oncology Research, Vol.32, No.4, pp. 737-752, 2024, DOI:10.32604/or.2023.042925 - 20 March 2024

    Abstract Kidney Renal Clear Cell Carcinoma (KIRC) is a malignant tumor that carries a substantial risk of morbidity and mortality. The MMP family assumes a crucial role in tumor invasion and metastasis. This study aimed to uncover the mechanistic relevance of the MMP gene family as a therapeutic target and diagnostic biomarker in Kidney Renal Clear Cell Carcinoma (KIRC) through a comprehensive approach encompassing both computational and molecular analyses. STRING, Cytoscape, UALCAN, GEPIA, OncoDB, HPA, cBioPortal, GSEA, TIMER, ENCORI, DrugBank, targeted bisulfite sequencing (bisulfite-seq), conventional PCR, Sanger sequencing, and RT-qPCR based analyses were used in the… More >

  • Open Access

    ARTICLE

    Characterization of prognosis and immune infiltration by a novel glutamine metabolism-related model in cutaneous melanoma

    MENGQIN ZHU1,2,3,4,#, TIANYI XU5,#, HAN ZHANG3,4, XIN FAN3,4, YULAN WANG6, JIAJIA ZHANG3,4, FEI YU1,2,3,4,*

    BIOCELL, Vol.47, No.9, pp. 1931-1945, 2023, DOI:10.32604/biocell.2023.028968 - 28 September 2023

    Abstract Glutamine metabolism (GM) plays an important role in tumor growth and proliferation. Skin cutaneous melanoma (SKCM) is a glutamine-dependent cancer. However, the molecular characteristics and action mechanism of GM on SKCM remain unclear. Therefore, we aimed to explore the effects of GM-related genes on survival, clinicopathological characteristics, and the tumor microenvironment in SKCM. In this study, 682 SKCM samples were obtained from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Consensus clustering was used to classify SKCM samples into distinct subtypes based on 41 GM-related genes. Differences in survival, immune infiltration, clinical… More > Graphic Abstract

    Characterization of prognosis and immune infiltration by a novel glutamine metabolism-related model in cutaneous melanoma

  • Open Access

    ARTICLE

    Deciphering key genes involved in cisplatin resistance in kidney renal clear cell carcinoma through a combined in silico and in vitro approach

    MUNEEBA MALIK1, MAMOONA MAQBOOL2, TOOBA NISAR3, TAZEEM AKHTER4, JAVED AHMED UJAN5,6, ALANOOD S. ALGARNI7, FAKHRIA A. AL JOUFI8, SULTAN SHAFI K. ALANAZI9, MOHAMMAD HADI ALMOTARED10, MOUNIR M. SALEM BEKHIT11, MUHAMMAD JAMIL12,*

    Oncology Research, Vol.31, No.6, pp. 899-916, 2023, DOI:10.32604/or.2023.030760 - 15 September 2023

    Abstract The low survival rate of Kidney renal clear cell carcinoma (KIRC) patients is largely attributed to cisplatin resistance. Rather than focusing solely on individual proteins, exploring protein-protein interactions could offer greater insight into drug resistance. To this end, a series of in silico and in vitro experiments were conducted to identify hub genes in the intricate network of cisplatin resistance-related genes in KIRC chemotherapy. The genes involved in cisplatin resistance across KIRC were retrieved from the National Center for Biotechnology Information (NCBI) database using search terms as “Kidney renal clear cell carcinoma” and “Cisplatin resistance”. The genes… More >

  • Open Access

    ARTICLE

    ABCC8 is correlated with immune cell infiltration and overall survival in lower grade glioma

    LIPING GONG1, MING JIA2,*

    BIOCELL, Vol.47, No.1, pp. 109-123, 2023, DOI:10.32604/biocell.2023.024620 - 26 September 2022

    Abstract ATP binding cassette subfamily C member 8 (ABCC8) encodes a protein regulating the ATP-sensitive potassium channel. Whether the level of ABCC8 mRNA in lower grade glioma (LGG) correlates with immune cell infiltration and patient outcomes has not been evaluated until now. Comparisons of ABCC8 expression between different tumors and normal tissues were evaluated by exploring publicly available datasets. The association between ABCC8 and tumor immune cell infiltration, diverse gene mutation characteristics, tumor mutation burden (TMB), and survival in LGG was also investigated in several independent datasets. Pathway enrichment analysis was conducted to search for ABCC8-associated… More >

  • Open Access

    ARTICLE

    Comprehensive analysis reveals an arachidonic acid metabolism-related gene signature in patients with pancreatic ductal adenocarcinoma

    HUILI ZHU1, LINA XIAO1, XIA YIN1, SHIBING XIANG1, CHUNHUI WANG2,*

    BIOCELL, Vol.46, No.10, pp. 2241-2256, 2022, DOI:10.32604/biocell.2022.020389 - 13 June 2022

    Abstract Pancreatic ductal adenocarcinoma (PDAC) is highly heterogeneous, making its prognosis prediction difficult. The arachidonic acid (AA) cascade is involved in carcinogenesis. Therefore, the metabolic enzymes of the AA cascade consist of lipoxygenases (LOXs), phospholipase A2s (PLA2s), and cyclooxygenases (COXs) along with their metabolic products, including leukotrienes. Nevertheless, the prognostic potential of AA metabolism-associated PDAC has not been explored. Herein, the mRNA expression patterns and the matching clinical information of individuals with PDAC were abstracted from online data resources. We employed the LASSO Cox regression model to develop a multigene clinical signature in the TCGA queue.… More >

  • Open Access

    ARTICLE

    MiR-16-5p plays an inhibitory role in human non-small cell lung cancer through Fermitin family member 2

    JUNQI GUO1,2,#, YUN YANG1,2,#, WEI ZHAO1,2, ZHONGHAI YAN3, XIA YANG4, YUNFEI YAN1,2, RUIMIN HAO1,2, JINXIA HU1,2,*, FEI JIAO1,2,*

    BIOCELL, Vol.45, No.3, pp. 627-638, 2021, DOI:10.32604/biocell.2021.013496 - 03 March 2021

    Abstract Increasing evidence indicates that aberrant expressions of some microRNAs are associated with cancer progression. However, the roles and biological mechanisms of miRNA-16-5p in human non-small cell lung cancer (NSCLC) are not to be well studied. Here, we validated that the expression of miR-16-5p was decreased significantly in NSCLC samples and cell lines. The correlation between the clinicopathological features of NSCLC and the miR-16- 5p expression showed that the expression of miR-16-5p in non-small cell lung cancer was linked with the advanced TNM stage, positive lymph node metastasis, with short overall survival (OS). Also, a negative More >

  • Open Access

    ARTICLE

    Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study

    Ping Wen*, Sheng-Duo Chen*, Jia-Rui Wang, Ying-He Zeng*

    Oncology Research, Vol.27, No.5, pp. 583-592, 2019, DOI:10.3727/096504018X15368325811545

    Abstract This study evaluated the difference in treatment response and survival profiles between drug-eluting bead transarterial chemoembolization (DEB-TACE) and conventional transarterial chemoembolization (cTACE) treatments in Chinese hepatocellular carcinoma (HCC) patients. A total of 120 HCC patients were consecutively enrolled in this prospective cohort study, which showed that DEB-TACE achieved higher complete response (CR) (30.8%) compared with cTACE (7.4%) with no difference in overall response rate (ORR) for patients treated with DEB-TACE and cTACE (80.8% vs. 73.5%). In addition, DEB-TACE was associated with a lower rate of progressive disease (PD) compared with cTACE (1.9% vs. 11.8%). With… More >

  • Open Access

    ARTICLE

    Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence From a Retrospective Study

    Xiaoting Wei, Lili Mao, Zhihong Chi, Xinan Sheng, Chuanliang Cui, Yan Kong, Jie Dai, Xuan Wang, Siming Li, Bixia Tang, Bin Lian, Xieqiao Yan, Xue Bai, Li Zhou, Jun Guo, Lu Si

    Oncology Research, Vol.27, No.4, pp. 495-501, 2019, DOI:10.3727/096504018X15331163433914

    Abstract Melanoma is an aggressive malignancy with a poor prognosis. Current studies show that imatinib treatment is a promising approach in treating advanced melanoma patients harboring c-Kit mutations or amplifications. We retrospectively analyzed the clinical medical records of 78 patients with metastatic melanoma harboring c-Kit mutations or amplifications. These patients were treated with imatinib at a dose of 400 mg/day continuously unless intolerable toxicities or disease progression occurred. Endpoints for exploration included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease of control rate (DCR). The median OS and PFS of all patients were More >

  • Open Access

    REVIEW

    Molecularly Targeted Drugs Plus Radiotherapy and Temozolomide Treatment for Newly Diagnosed Glioblastoma: A Meta-Analysis and Systematic Review

    Jiahao Su*, Meiqin Cai*, Wensheng Li*, Bo Hou, Haiyong He, Cong Ling,Tengchao Huang, Huijiao Liu, Ying Guo*

    Oncology Research, Vol.24, No.2, pp. 117-128, 2016, DOI:10.3727/096504016X14612603423511

    Abstract Glioblastoma (GBM) is the most common primary malignant brain tumor that nearly always results in a bad prognosis. Temozolomide plus radiotherapy (TEM+RAD) is the most common treatment for newly diagnosed GBM. With the development of molecularly targeted drugs, several clinical trials were reported; however, the efficacy of the treatment remains controversial. So we attempted to measure the dose of the molecularly targeted drug that could improve the prognosis of those patients. The appropriate electronic databases (PubMed, MEDLINE, EMBASE, and the Cochrane Library) were searched for relevant studies. A meta-analysis was performed after determining which studies… More >

Displaying 1-10 on page 1 of 9. Per Page